<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928744</url>
  </required_header>
  <id_info>
    <org_study_id>2011/43</org_study_id>
    <secondary_id>2011-A00964-37</secondary_id>
    <nct_id>NCT02928744</nct_id>
  </id_info>
  <brief_title>Evaluation of the Reversibility of the Bronchial Obstruction by Impulse Oscillometry Technique in Chronic Obstructive Pulmonary Disease (COPD): Correlation With Functional Features Measured by Plethysmography and Dyspnoea</brief_title>
  <acronym>OSCILLOREVERS</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Limitation of expiratory flows is considered as the main determiner of dynamic distension and&#xD;
      dyspnoea in chronic obstructive pulmonary disease (COPD). The analysis of proximal and distal&#xD;
      resistances should allow to better appreciate the functional impact.&#xD;
&#xD;
      This study should also allow to specify the best parameters in respiratory functional&#xD;
      explorations useful for the follow-up in COPD and to specify the relevance of functional&#xD;
      indications other than the forced expiration volume at 1 second (FEV1) or the functional&#xD;
      residual capacity (FRC) to estimate in a more relevant way the clinical improve with the&#xD;
      increase of the therapeutic load (increase of posology, association of two bronchodilatators,&#xD;
      addition of an anti-inflammatory drug, thus etc…) at already handled patients suffering from&#xD;
      a persistent dyspnoea insufficiently relieved.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment difficulties&#xD;
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of obstruction reversibility</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>COPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>COPD</intervention_name>
    <description>Plethysmography</description>
    <arm_group_label>COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>COPD</intervention_name>
    <description>Forced oscillations</description>
    <arm_group_label>COPD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COPD with dyspnoea with Medical Research Council scale (MRC) &gt;1,&#xD;
&#xD;
          -  No exacerbation for 6 weeks&#xD;
&#xD;
          -  No bronchodilatator short action(share) (ß 2 agonist or ipratropium) within 6 hours&#xD;
             before the respiratory evaluation and the test of reversibility.&#xD;
&#xD;
          -  Patient under current treatment (ß2 long-acting agonist (LABA) or anticholinergic&#xD;
             long-acting (LLAMA(LAMA)) or LABA-corticoid association inhaled (CSI), or triples&#xD;
             LABA-CSI-LAMA association) stable for at least 4 weeks, and taken for at least the 1&#xD;
             hour the day of the visit&#xD;
&#xD;
          -  Having given a written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient Under 18&#xD;
&#xD;
          -  Other respiratory illness&#xD;
&#xD;
          -  Clinically significant left cardiac failure&#xD;
&#xD;
          -  Obesity with BMI &gt; 35 kg / m2)&#xD;
&#xD;
          -  Unable to perform respiratory evaluations&#xD;
&#xD;
          -  Contraindication to the salbutamol or to the ipratropium bromide or to one of its&#xD;
             components&#xD;
&#xD;
          -  Pregnant or breast-feeding woman&#xD;
&#xD;
          -  Unable to agree&#xD;
&#xD;
          -  No social security scheme&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène Neveu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Foch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2016</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Resistance</keyword>
  <keyword>Forced oscillations</keyword>
  <keyword>Dyspnea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

